KURA ONCOLOGY, INC. Net Cash Provided by (Used in) Financing Activities, Continuing Operations
KURA ONCOLOGY, INC. (KURA) reported Net Cash Provided by (Used in) Financing Activities, Continuing Operations of $57.65 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations · last filed 2018-05-08
- KURA ONCOLOGY, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2018-03-31 was $57.65M, a 1152900.00% increase year-over-year.
- KURA ONCOLOGY, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-12-31 was -$338.00K.
- KURA ONCOLOGY, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-09-30 was $53.71M.
- KURA ONCOLOGY, INC. net cash provided by (used in) financing activities, continuing operations for the quarter ending 2017-06-30 was $189.00K.
- KURA ONCOLOGY, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2017 was $53.57M, a 618.73% increase from fiscal 2016.
- KURA ONCOLOGY, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2016 was $7.45M, a 92.75% decline from fiscal 2015.
- KURA ONCOLOGY, INC. net cash provided by (used in) financing activities, continuing operations for fiscal 2015 was $102.87M.
| Period end | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 1 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 4 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Financing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|---|
| 2018-03-31 | $57.65M 10-Q · filed 2018-05-08 | $57.31M derived: sum of 2 quarters · filed 2018-05-08 | $111.02M derived: sum of 3 quarters · filed 2018-05-08 | $111.21M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-12-31 | -$338.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $53.37M derived: sum of 2 quarters · filed 2018-03-12 | $53.56M derived: sum of 3 quarters · filed 2018-03-12 | $53.57M 10-K · filed 2018-03-12 | ||
| 2017-09-30 | $53.71M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $53.90M derived: sum of 2 quarters · filed 2017-11-07 | $53.91M 10-Q · filed 2017-11-07 | $53.91M derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-06-30 | $189.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $194.00K 10-Q · filed 2017-08-07 | $194.00K derived: sum of 3 quarters · filed 2018-05-08 | $194.00K derived: sum of 4 quarters · filed 2018-05-08 | ||
| 2017-03-31 | $5.00K 10-Q · filed 2018-05-08 | $5.00K derived: sum of 2 quarters · filed 2018-05-08 | $5.00K derived: sum of 3 quarters · filed 2018-05-08 | |||
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-12 | $0.00 derived: sum of 2 quarters · filed 2018-03-12 | $7.45M 10-K · filed 2018-03-12 | |||
| 2016-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | $7.45M 10-Q · filed 2017-11-07 | ||||
| 2016-06-30 | $7.45M 10-Q · filed 2017-08-07 | |||||
| 2015-12-31 | $50.28M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-14 | $50.03M derived: sum of 2 quarters · filed 2017-03-14 | $46.29M derived: sum of 3 quarters · filed 2017-03-14 | $102.87M 10-K · filed 2017-03-14 | ||
| 2015-09-30 | -$252.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | -$3.99M derived: sum of 2 quarters · filed 2016-11-07 | $52.59M 10-Q · filed 2016-11-07 | |||
| 2015-06-30 | -$3.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-10 | $52.84M 10-Q · filed 2016-08-10 | ||||
| 2015-03-31 | $56.58M 10-Q · filed 2016-05-11 | |||||
| 2014-12-31 | $2.00M 10-K · filed 2016-03-17 | |||||
| 2014-09-30 | $109.00K 10-Q · filed 2015-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 |